A $46-$year$-$old man is currently enrolled in a phase III study of a drug for severe diabetic neuropathy. While the study is ongoing, a new drug becomes commercially available that may have equal or greater benefit to the subject. The investigator should do which of the following?

Withhold this new information to avoid confusing the subject with other treatment options or alternatives

Discuss the pros and cons of both the investigational drug and the commercially available drug and then allow the subject to decide whether to withdraw from the research to take the new drug

Tell the subject about the new drug but discourage him from switching treatments until the study is completed

Do not tell the subject about the new drug because physicians have the right to try out new treatments with their patients